← Back to Search

PD-1 Inhibitor

Telatinib + Keytruda for Stomach and Liver Cancer

Phase 2

Waitlist Available

Led By Andrew Hendifar, MD, MPH

Research Sponsored by Andrew Hendifar, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years

Awards & highlights

Study Summary

This trial is testing a new cancer drug (telatinib) in combination with another drug (Keytruda) to see if it can extend progression-free survival in patients with stomach, gastroesophageal junction, or liver cancer.

Who is the study for?

Adults with advanced stomach, gastroesophageal junction cancers or hepatocellular carcinoma that have progressed after prior treatments and are PD-L1-positive. They must be able to swallow tablets, not have uncontrolled infections or certain other health conditions, and agree to use contraception.Check my eligibility

What is being tested?

The trial is testing the combination of Telatinib and Keytruda in patients with specific advanced cancers. It's an open-label study focusing on how these drugs affect the time a patient lives without their disease getting worse.See study design

What are the potential side effects?

Possible side effects include high blood pressure, bleeding events, nonhealing wounds or ulcers, gastrointestinal issues like fistulas or perforations, liver problems due to hepatitis B or cirrhosis, immune system complications including pneumonitis and potential allergic reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression-free survival

Secondary outcome measures

Disease control rate

Incidence and severity of adverse events

Overall response rate

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: telatinib + KeytrudaExperimental Treatment2 Interventions

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Andrew Hendifar, MDLead Sponsor

5 Previous Clinical Trials

106 Total Patients Enrolled

EOC PharmaUNKNOWN

Andrew Hendifar, MD, MPHPrincipal Investigator - Cedars-Sinai Medical Center

Cedars-Sinai Medical Center, Sound Physicians Platinum Group Pc

Tulane University School Of Medicine (Medical School)

2 Previous Clinical Trials

40 Total Patients Enrolled

Media Library

Keytruda (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04798781 — Phase 2

Liver Cancer Research Study Groups: telatinib + Keytruda

Liver Cancer Clinical Trial 2023: Keytruda Highlights & Side Effects. Trial Name: NCT04798781 — Phase 2

Keytruda (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04798781 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Telatinib been evaluated in other clinical experiments?

"Presently, Telatinib is being studied in 961 live studies; 122 of which are located in Phase 3. While Houston, Texas has a concentration of trials looking at this medication's efficacy and safety profile, there are 35 727 locations worldwide that have active research projects on the drug."

Answered by AI

How many individuals have been recruited to participate in this experiment?

"Indeed, the data hosted on clinicaltrials.gov confirms that this investigation is currently accepting participants. Initially posted in July 28th 2021, with an update on September 1st 2022; 45 volunteers across 8 medical centres are being recruited for the trial."

Answered by AI

What therapeutic benefits has Telatinib been demonstrated to provide?

"Telatinib is a highly successful treatment for malignant neoplasms, and it can also help patients with conditions like microsatellite instability high and unresectable melanoma control the growth of their disease after chemotherapy."

Answered by AI

Has Telatinib been authorized by the FDA for use?

"Our evaluation of Telatinib's safety rate is a 2 as it has only been tested in Phase 2 trials, indicating some evidence for its security but none to attest to its efficacy."

Answered by AI

Is there still capacity for patient participation in this research?

"Affirmative. According to clinicaltrials.gov, this medical trial is still in search of participants and was initially posted on July 28th 2021. The last edit occurred on September 1st 2022, with 45 patients being sought from 8 different sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Andrew Hendifar, MD 2021. "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04798781.

All > No Stomach For Cancer > Hepatocellular Carcinoma